- Global Pharma News & Resources

Increasing incidence of cardiovascular disease will boost the dyslipidemia therapeutics market, forecast to grow at a CAGR of 6%

Noida,Uttar Pradesh, India,Mar 04 2021 (WiredRelease) Report Ocean Pvt Ltd–:Global Dyslipidemia Therapeutics Market is estimated to see healthy growth, pegged at a CAGR of ~6% during the forecast period 2020-2025. Dyslipidemia is one of the metabolic disorders described by unbalanced levels and thickness of lipoproteins and triglycerides. The condition also includes protein deficiency and overproduction. These disorders can be caused by increased serum total cholesterol, triglyceride concentrations, low-density lipoprotein (LDL) cholesterol, and a reduction in the high-density lipoprotein (HDL) cholesterol concentration. These conditions are mainly related to cardiovascular or coronary heart disease. The other cause of this disease comprises genetic predisposition and hypothyroidism. The rise in triglyceride concentration might also lead to diabetes mellitus, obesity, and hypothyroidism. The treatment of dyslipidemia includes nutrition supplements, lifestyle modification, exercise & weight reduction, and drug therapy.

Get more information:

The global market for dyslipidemia therapeutics is expected to be driven by increasing dyslipidemia and cardiovascular disease, growing obese population prone to cardiovascular disease due to a sedentary lifestyle. A few of the market drivers are the growing R&D activities by leading players to develop novel drugs, increase diagnosis rate among patient populations, and increase awareness in developing economies.  Moreover, the increasing research activities on the stain and non-stain-based therapeutics for cardiovascular and associated disease, pre-clinical research activities, and growing collaboration between research institutes, biotechnology, and biopharmaceuticals companies are expected to drive the market during the forecast period. However, the high cost of drug development and pre-clinical activities, high cost of therapeutics to the end-users, stringent regulation, and lengthy approval process might hamper the market growth to some extent.

The dyslipidemia drugs market is expected to witness significant growth over the forecast period due to pipeline drugs under clinical trial phases of development. Many drugs under trials are being tested to be used to treat hypercholesterolemia and other cholesterol-associated metabolism disorders in specific patient populations. Under development, drugs are expected to offer returns over the present drugs, including higher efficacy, safety, and better tolerance by the metabolizing organ.

Other substantial factors that are expected to drive the dyslipidemia drugs market are upcoming biotechnological products such as monoclonal antibodies for the treatment of lipid disorders, diseases inducing lifestyle habits such as tobacco smoking and chewing, high salt intake, high intake of cholesterol, and weight gain, which led to rising in level of high-density lipoprotein and low-density lipoprotein. However, the high capital requirement for biotechnology-based R&D drug development is expected to restrain market growth to some extent

Segmentation Overview of the Global Dyslipidemia Therapeutics Market

The dyslipidemia therapeutics market has been segmented into Product Type and Distribution Channel. These major market segments are further categorized into various sub-segments to study the market in detail.

By Product Type Outlook
Statin Drugs (High-intensity, Moderate-intensity, Low-intensity)
Non-Statin Lipid–Lowering Drugs (Bile Acid Sequestrants, Cholesterol Absorption Inhibitor, Fibrates, Nicotinic Acid, PCSK9 Monoclonal Antibodies, omega-3 Fatty Acids, Combination Products)

By Distribution Channel Outlook (Hospitals Pharmacies, Drug Store, Online Pharmacies, Retail Pharmacies)

Key Players Insights

Pfizer Inc., Bayer AG, Sanofi, GlaxoSmithKline plc., Merck & Co., Inc., Abbott, Novartis AG, Gilead Sciences, Inc., Johnson & Johnson Services Inc., Astellas Pharma Inc., and Bristol-Myers Squibb Company, among others, are some significant companies included in the global dyslipidemia therapeutics market research study.

For Purchase Enquiry at

This content has been published by Report Ocean Pvt Ltd company. The WiredRelease News Department was not involved in the creation of this content. For press release service enquiry, please reach us at

Editor Details

Last Updated: 04-Mar-2021